Zevra Therapeutics Announced Late Saturday, Presentation Of Full Data Set On The Cardiovascular Safety And Pharmacokinetics Of SDX, The Sole API In KP1077, In Healthy Volunteers At Psych Congress 2023
Portfolio Pulse from Charles Gross
Zevra Therapeutics has presented study data at the Psych Congress 2023, highlighting the cardiovascular safety and pharmacokinetics of serdexmethylphenidate (SDX), the sole active pharmaceutical ingredient in KP1077. The study results affirm that SDX is safe and well-tolerated at higher doses and has no greater cardiovascular safety risk than other methylphenidate products currently being used off-label for the treatment of idiopathic hypersomnia (IH).
September 10, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive study results on the safety of SDX, the sole API in Zevra's investigational candidate KP1077, could boost investor confidence in the company's product pipeline.
The positive study results on the safety of SDX, the sole API in Zevra's investigational candidate KP1077, could boost investor confidence in the company's product pipeline. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100